BioNTech says Sobi's Oelkers will replace Sahin as CEO (updated)
03/08/2026 10:22
UPDATE 1-BioNTech says Sobi's Oelkers will replace Sahin as CEO Adds details from statement, context
Aug 3 (Reuters) - German biotech firm BioNTech 22UAy.DE said on Monday that Sobi's SOBIV.ST CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
Oelkers will take on the role from February 1, 2027 at latest, the company said, after serving as CEO at the Stockholm-listed biopharmaceutical company since 2017.
BioNTech announced in March its two co-founders and leading executives, Sahin and Chief Medical Officer Oezlem Tuereci, would leave the COVID-19 vaccine maker by the end of the year to start a new venture.
(Reporting by Linda Pasquini, Editing by Ludwig Burger)
((linda.pasquini@thomsonreuters.com; +48 58 7785261;))
Recent news on Swedish Orphan Biovitrum AB (publ)
See all newsTop of the Street: SOBI, Sonova, BAT, Imperial Brands
SOBI slips after Ionis lowers Tryngolza sales forecast
Brief: Swedish Orphan Biovitrum Executive Sells, Buys Shares
Europe Research Roundup: Centrica, Fuchs, URW
Brief: Swedish Orphan Biovitrum Proposes Börje Ekholm As New Chair And Board Member At 2027 AGM